株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のクラミジア感染症診断市場:成長、動向、および予測(2020年~2025年)

Chlamydia Infection Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921904
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.80円で換算しております。
Back to Top
世界のクラミジア感染症診断市場:成長、動向、および予測(2020年~2025年) Chlamydia Infection Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 112 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

世界のクラミジア感染症断市場は、クラミジアの流行と従来の技術から分子診断への主な移行により、急速に成長しています。また、臨床検査ベースの検査は、同市場のシェアを大きく占めており、中でも、クラミジアトラコマチスの遺伝物質であるDNAを検出する分子検査である核酸増幅検査(NAAT)が推奨されています。さらに、新しい診断ツールに関しては、薬やワクチンよりもわずかなコストで非常に短い時間で開発でき、今後の市場機会の一つに挙げられます。

当レポートは世界のクラミジア感染症断市場について調査しており、市場機会や動向、成長および阻害要因、検査タイプ・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • クラミジアの発生率の上昇と有病率の増加
    • 迅速なテストに対する需要の増加
  • 市場阻害要因
    • 専門のSTDクリニックを訪れる患者に関する社会的スティグマ
    • 医療へき地での大勢のクラミジア感染患者
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • テストタイプ別
    • 文化試験
    • 核酸増幅試験(NAAT)
    • 直接蛍光抗体法
    • 血清検査
    • その他
  • エンドユーザー別
    • 病院
    • 診断センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • BIO-RAD LABORATORIES
    • Danaher Corporation (Cepheid)
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd
    • Hologic, Inc.
    • QUIDEL CORPORATION
    • SAVYON DIAGNOSTICS
    • TRINITY BIOTECH

第7章 市場機会および今後の動向

目次
Product Code: 67399

Market Overview

Owing to the rising prevalence of chlamydia and major shift from conventional technologies to molecular diagnostics the market studied is growing rapidly. In 2016, WHO estimated 376 million new infections with 1 of 4 being STIs, out of which, the incidence of chlamydia was 127 million, gonorrhea was 87 million, and syphilis was 6.3 million. Furthermore, there is a growing focus on rapid testing since it delivers a quick results. In 2018, the NIBIB-funded researchers authorized a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby curtailing further spread of disease. There is a negative social perception of STDs, as they are caused due to sexual interactions. Hence, people are more conscious about their privacy and social status, when it comes to STD testing, which is limiting the growth of the market studied.

Scope of the Report

Chlamydia is a curable and common, sexually transmitted infection that may not cause symptoms. It spreads through vaginal, anal, and oral sex. The infection is carried in semen (cum), pre-cum, and vaginal fluids. Chlamydia can infect the penis, vagina, cervix, anus, urethra, eyes, and throat.

Key Market Trends

Laboratory-Based Tests dominates the Global Chlamydia Infection Diagnostics Market

  • The Nucleic Acid Amplification Test (NAAT) is the recommended method. It is a molecular test that detects DNA, the genetic material of Chlamydia trachomatis.
  • The method is usually more sensitive and specific than the other chlamydia tests and it can be performed on a vaginal swab taken from women, as well as on urine from both men and women, and thus it eliminates the requirement for a pelvic exam in women.
  • Most of the time, NAATs can be used with both urine and vaginal samples for women. However, only some are approved for use with samples taken from men as well.
  • Furthermore, new diagnostic tools can be developed for a fraction of the cost and in much less time than either a drug or a vaccine which suggests that focused funding and effort should be able to produce viable tools in a relatively short period of time.

North America Dominates the Global Chlamydia Infection Diagnostics Market

North America holds a leading position in the Chlamydia Infection Diagnostics market during the forecast period. In 2017, a total of 1,708,569 chlamydial infections were reported to the Centre for Disease Prevention and Control (CDC) in 50 states of the United States. During 2016-2017, the rate of reported cases increased by 6.9%, from 494.7 to 528.8 cases per 100,000 population. The National Health and Nutrition Examination Survey (NHANES) is a nationally representative survey of the US civilian, a non-institutionalized population that provides an important measure of chlamydia disease burden in respondents aged 14-39 years. In March 2019, USFDA granted clearance to diagnostic tests for extragenital testing for chlamydia and gonorrhea, Aptima Combo 2 Assay, to Hologic Inc. and Xpert CT/NG to Cepheid. Hence, the high rate of diagnosis, high adoption and awareness among the people and the introduction of new and technologically advanced tests are also contributing to the growth of the market in North America.

Competitive Landscape

Currently, many private pharmaceuticals and biotechnology companies drive, direct and coordinate the development and introduction of novel products into the market which is easily affordable and accessible. Some of the key innovations in the market are: In July 2019, Nurx, the San Francisco-based startup launched three new test kits, which will test for conditions such as chlamydia, gonorrhea and syphilis.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence Rates and Increasing Prevalence Rates of Chlamydia
    • 4.2.2 Growing Demand for rapid testing
  • 4.3 Market Restraints
    • 4.3.1 Social Stigma Associated with Patients Visiting Specialized STD Clinics
    • 4.3.2 Huge Proportion of Patients Infected with Chlamydia in Out-of-reach Geographic Areas
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test Type
    • 5.1.1 Culture Tests
    • 5.1.2 Nucleic Acid Amplification Test (NAAT)
    • 5.1.3 Direct Fluorescent Antibody Test
    • 5.1.4 Serology Tests
    • 5.1.5 Others
  • 5.2 End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 BIO-RAD LABORATORIES
    • 6.1.4 Danaher Corporation (Cepheid)
    • 6.1.5 DiaSorin SpA
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Hologic, Inc.
    • 6.1.8 QUIDEL CORPORATION
    • 6.1.9 SAVYON DIAGNOSTICS
    • 6.1.10 TRINITY BIOTECH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top